Field Notes — November 16, 2026

Tandem and MiniMed Each Cleared the Only Seven-Day Tubeless Insulin Pump

All Field Notes
November 16, 2026 Medical Devices

Tandem Diabetes Care announced on Friday that the FDA had cleared a tubeless version of its Mobi pump. MiniMed followed on Monday with clearance for MiniMed Fit. Each company called its device the world's first and only tubeless pump with up to seven days of wear, and each claim holds inside its own footnote. The trade coverage frames the week as two challengers catching Insulet at once. Neither has caught anyone yet. Both launches start in 2027, and a clinician reading the two matching headlines learns nothing about which pump to choose.

Where the two claims live

Tandem's footnote says the tubeless infusion set is cleared for up to seven days of wear and the cartridge for three days of use, so a Mobi wearer still changes the cartridge every three days. MiniMed built its headline on that three-day cartridge. MiniMed Fit promises "zero interruptions," meaning no charging and no cartridge change for the whole wear period. It also holds 300 units of insulin. By MiniMed's count, Omnipod and the Mobi tubeless hold 200. MiniMed's claim has a footnote too: seven-day wear holds for a total daily dose under 42 units, so a patient who needs more insulin changes the pump sooner.

Each company picked the axis where it leads and qualified the claim until it held. An endocrinologist comparing the two will skip both headlines and read wear time per change, reservoir size, and the daily dose at which MiniMed's seven days stops applying. The 300-unit reservoir and the 42-unit threshold belong to MiniMed alone. A rival can print the same superlative, as these two did three days apart, but it can't print another company's reservoir size.

What the clearance doesn't cover

Tandem plans a limited launch, then full U.S. availability in the first half of 2027. William Blair analysts told MedTech Dive the limited phase buys time to build manufacturing capacity and update pharmacy contracts. MiniMed plans an early customer phase and a phased rollout in the spring. Its chief executive, Que Dallara, said in September that manufacturing is among the hardest parts of a patch pump launch, because the product is sterile and has to be made in high volume.

Both companies will sell tubeless supplies through the pharmacy. Tandem will offer its tubeless sets and cartridges there only to customers with pharmacy benefits. The company puts Mobi's pharmacy coverage at about half of insured U.S. lives and expects more through 2027, and William Blair says Tandem's leaders see the tubeless option as a lever in payer talks. For an insured patient outside that half, the clearance date and the day they can get the product may sit months apart.

The pump underneath

Five days before Tandem's announcement, MedTech Dive reported a correction covering more than 80,900 Mobi pumps. Friction inside the drive module can sap motor power. When the motor slows past a threshold, the pump reads it as a blocked line, raises a false occlusion alarm and stops insulin until the user responds. As of Oct. 29, Tandem had 230 reports of adverse events that needed medical intervention or hospitalization, and no deaths.

The tubeless option is a new infusion set and cartridge for that same pump. Tandem's release says in-warranty Mobi pumps already work with it, which analysts count as a strength, since current users can switch without buying hardware. Sharing the pump also carries the drive module into the tubeless launch. Tandem says it has taken steps during testing to keep the problem from recurring, and a clinic prescribing the tubeless option will want to know whether those steps cover the pumps already in patients' hands.

From the product seat, the question I'd put to my own launch plan is which of its claims a competitor could match by Friday. A reservoir size, a change schedule and a coverage map are harder to copy than a superlative, and they come out of the manufacturing and payer work a launch needs anyway. The drive module has a parallel in Synchron, which paused trial enrollment last week over a cable and decided to bring the part in-house. In both cases the launch schedule depends on a component no press release mentions.

Dave's take

Neither newcomer caught Insulet with a clearance. The contest I'd watch runs through the first half of 2027, in pharmacy contracts and production lines, and the figures that will decide it, manufacturing capacity and final coverage, aren't public yet.

From Dave’s video library

In today's Monday MedTech, I look at Virtuoso's bladder tumor robot, the first device in a new FDA device class.

Dave Saunders

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →